The regulatory green light allows Wakix (pitolisant) to address a critical symptom in younger populations. While the drug was previously cleared for adults and for pediatric narcolepsy patients without cataplexy, this expansion significantly broadens its clinical utility. According to Chief Executive Officer Jeffrey Dayno, the treatment’s status as a non-controlled substance is a significant differentiator in the market, potentially simplifying the prescribing process for physicians and families compared to traditional scheduled stimulants.

Market Position and Future Growth

Harmony is currently pursuing pediatric exclusivity for the treatment to solidify its competitive advantage. Beyond this approval, the company is looking toward long-term lifecycle management, with Dayno confirming that next-generation formulations of pitolisant have utility patents filed through 2044. These efforts are part of a broader strategy to expand the drug’s application across additional indications within the sleep medicine sector.

Investors responded positively to the announcement, sending shares of Harmony up 3.9% to $37.42 during Tuesday afternoon trading. The company remains focused on scaling its reach as the only provider of a non-scheduled option for the full spectrum of narcolepsy patients, including those aged six and older.